Analysis

Palvella Therapeutics, Inc. (PVLA) Stock Analysis

Palvella Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to PVLA.

websitePVLA/analysis/PVLA

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to PVLA.

Stock profile

Ticker

PVLA

Asset type

Stock

Market cap

$1.62B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Palvella Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • PVLA primary listing
  • PI6

Latest Palvella Therapeutics, Inc. news

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted ...

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on devel...

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PAC...

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on develo...

Research sections

Valuation

Review valuation context for Palvella Therapeutics, Inc..

Future growth

Review future growth context for Palvella Therapeutics, Inc..

Past performance

Review past performance context for Palvella Therapeutics, Inc..

Financial health

Review financial health context for Palvella Therapeutics, Inc..

Dividend

Review dividend context for Palvella Therapeutics, Inc..

Management

Review management context for Palvella Therapeutics, Inc..

Ownership

Review ownership context for Palvella Therapeutics, Inc..

Other information

Review other information context for Palvella Therapeutics, Inc..

Community

Review community context for Palvella Therapeutics, Inc..